ATE384718T1 - Furazanobenzimidazole - Google Patents
FurazanobenzimidazoleInfo
- Publication number
- ATE384718T1 ATE384718T1 AT04733874T AT04733874T ATE384718T1 AT E384718 T1 ATE384718 T1 AT E384718T1 AT 04733874 T AT04733874 T AT 04733874T AT 04733874 T AT04733874 T AT 04733874T AT E384718 T1 ATE384718 T1 AT E384718T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- formula
- carbonyl group
- neoplastic
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03405365 | 2003-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE384718T1 true ATE384718T1 (de) | 2008-02-15 |
Family
ID=33462273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04733874T ATE384718T1 (de) | 2003-05-23 | 2004-05-19 | Furazanobenzimidazole |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7385061B2 (de) |
| EP (1) | EP1636215B1 (de) |
| JP (2) | JP4829791B2 (de) |
| CN (1) | CN100434428C (de) |
| AT (1) | ATE384718T1 (de) |
| CA (1) | CA2526026C (de) |
| CY (1) | CY1107422T1 (de) |
| DE (1) | DE602004011515T2 (de) |
| DK (1) | DK1636215T3 (de) |
| ES (1) | ES2300775T3 (de) |
| PL (1) | PL1636215T3 (de) |
| PT (1) | PT1636215E (de) |
| SI (1) | SI1636215T1 (de) |
| WO (1) | WO2004103994A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040034037A1 (en) * | 2002-02-06 | 2004-02-19 | Harbeson Scott L. | Heteroaryl compounds useful as inhibitors of GSK-3 |
| EP1723138B1 (de) * | 2004-02-11 | 2010-07-14 | Basilea Pharmaceutica AG | Substituierte benzimidazole und deren verwendung zur induktion von apoptose |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| EA021380B1 (ru) | 2009-07-27 | 2015-06-30 | Базилеа Фармацойтика Аг | Фуразанобензимидазолы в качестве пролекарств для лечения опухолевых или аутоиммунных заболеваний |
| PL2666015T3 (pl) * | 2011-01-21 | 2017-06-30 | Basilea Pharmaceutica Ag | Zastosowanie statminy jako biomarkera odpowiedzi lekowej na furazanobenzoimidazole |
| HUE031162T2 (en) | 2011-01-21 | 2017-07-28 | Basilea Pharmaceutica Ag | Use of Glu tubulin as a biomarker for drug response to furazanobenzimidazoles |
| WO2012098207A1 (en) * | 2011-01-21 | 2012-07-26 | Basilea Pharmaceutica Ag | Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles |
| HUE032187T2 (en) * | 2011-02-24 | 2017-09-28 | Basilea Pharmaceutica Ag | Use of acetylated tubulin as a biomarker for response to furazanobenzimidazoles |
| PL2691533T3 (pl) | 2011-03-29 | 2017-09-29 | Basilea Pharmaceutica Ag | Zastosowanie fosfo-Akt jako biomarkera odpowiedzi na leki |
| CN108139405B (zh) * | 2015-10-22 | 2022-06-10 | 巴斯利尔药物国际股份公司 | Eb1作为药物应答的生物标记物的用途 |
| CA3058695A1 (en) | 2017-04-26 | 2018-11-01 | Basilea Pharmaceutica International AG | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof |
| US20200150109A1 (en) | 2017-05-05 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases |
| EP3624790A1 (de) | 2017-05-16 | 2020-03-25 | Basilea Pharmaceutica International AG | Neuartige darreichungsprinzipien für arzneimittel zur behandlung von neoplastischen erkrankungen |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US20220031670A1 (en) | 2018-09-20 | 2022-02-03 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US20220370418A1 (en) | 2019-09-09 | 2022-11-24 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| CN111454254B (zh) | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
| GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| DE3100771A1 (de) * | 1981-01-13 | 1982-08-26 | USV Pharmaceutical Corp., Tuckahoe, N.Y. | Heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| DE4307105A1 (de) * | 1993-03-06 | 1994-09-08 | Cassella Ag | Hydroxymethylfurazancarbonsäurederivate |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US20040034037A1 (en) * | 2002-02-06 | 2004-02-19 | Harbeson Scott L. | Heteroaryl compounds useful as inhibitors of GSK-3 |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
-
2004
- 2004-05-19 PL PL04733874T patent/PL1636215T3/pl unknown
- 2004-05-19 EP EP04733874A patent/EP1636215B1/de not_active Expired - Lifetime
- 2004-05-19 DE DE602004011515T patent/DE602004011515T2/de not_active Expired - Lifetime
- 2004-05-19 CA CA2526026A patent/CA2526026C/en not_active Expired - Lifetime
- 2004-05-19 JP JP2006530690A patent/JP4829791B2/ja not_active Expired - Fee Related
- 2004-05-19 AT AT04733874T patent/ATE384718T1/de active
- 2004-05-19 PT PT04733874T patent/PT1636215E/pt unknown
- 2004-05-19 US US10/557,539 patent/US7385061B2/en not_active Ceased
- 2004-05-19 SI SI200430636T patent/SI1636215T1/sl unknown
- 2004-05-19 ES ES04733874T patent/ES2300775T3/es not_active Expired - Lifetime
- 2004-05-19 US US12/796,135 patent/USRE42890E1/en not_active Expired - Lifetime
- 2004-05-19 CN CNB2004800177608A patent/CN100434428C/zh not_active Expired - Fee Related
- 2004-05-19 WO PCT/IB2004/001723 patent/WO2004103994A1/en active IP Right Grant
- 2004-05-19 DK DK04733874T patent/DK1636215T3/da active
-
2008
- 2008-04-23 CY CY20081100454T patent/CY1107422T1/el unknown
-
2011
- 2011-06-21 JP JP2011137578A patent/JP5670266B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SI1636215T1 (sl) | 2008-06-30 |
| JP2011207909A (ja) | 2011-10-20 |
| ES2300775T3 (es) | 2008-06-16 |
| JP5670266B2 (ja) | 2015-02-18 |
| DK1636215T3 (da) | 2008-06-02 |
| PL1636215T3 (pl) | 2008-09-30 |
| WO2004103994A1 (en) | 2004-12-02 |
| PT1636215E (pt) | 2008-04-29 |
| EP1636215B1 (de) | 2008-01-23 |
| US7385061B2 (en) | 2008-06-10 |
| DE602004011515T2 (de) | 2009-01-29 |
| JP2006528238A (ja) | 2006-12-14 |
| CA2526026C (en) | 2012-03-20 |
| EP1636215A1 (de) | 2006-03-22 |
| CY1107422T1 (el) | 2012-12-19 |
| CN100434428C (zh) | 2008-11-19 |
| CA2526026A1 (en) | 2004-12-02 |
| US20070043061A1 (en) | 2007-02-22 |
| DE602004011515D1 (de) | 2008-03-13 |
| JP4829791B2 (ja) | 2011-12-07 |
| USRE42890E1 (en) | 2011-11-01 |
| CN1812986A (zh) | 2006-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107422T1 (el) | Φουραζανοβενζιμιδαζoλες | |
| NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
| DE602005022284D1 (de) | Substituierte benzimidazole und deren verwendung zur induktion von apoptose | |
| HUP0401889A2 (hu) | 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
| IS2376B (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
| NO20075169L (no) | Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme. | |
| TW200724136A (en) | Pharmaceutical compositions comprising PPAR modulator | |
| SE0302116D0 (sv) | Novel compounds | |
| HK1082250A1 (en) | Thiophene carboxamides as inhibitors of the enzymeikk-2 | |
| TW200616636A (en) | Novel compounds | |
| SE0302139D0 (sv) | Novel compounds | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| ATE381554T1 (de) | Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| SE0300092D0 (sv) | Novel compounds | |
| SE0402925D0 (sv) | Novel Compounds | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| SE0300456D0 (sv) | Novel compounds | |
| MXPA05010020A (es) | Derivados de oxamida. | |
| ATE485822T1 (de) | Phenylaminopyridine und phenylaminopyrazine | |
| SE0401763D0 (sv) | Compounds | |
| SE0303280D0 (sv) | Novel compounds | |
| SE0303090D0 (sv) | Novel compounds | |
| MXPA05014068A (es) | Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina. | |
| SE0302755D0 (sv) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1636215 Country of ref document: EP |